Drug research

Dordaviprone (ONC201)

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Dordaviprone

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial CancerNCT03485729	Jazz Pharmaceuticals	Phase 2	Terminated	2023-01-19Actual
ONC201 in Adults With Recurrent H3 K27M-mutant GliomaNCT03295396	Jazz Pharmaceuticals	Phase 2	Terminated	2022-12-31Actual
Oral ONC201 in Adult Recurrent GlioblastomaNCT02525692	Jazz Pharmaceuticals	Phase 2	Terminated	2023-04-17Actual
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)NCT05580562	Jazz Pharmaceuticals	Phase 3	Recruiting	2028-06Estimated

Jazz PharmaceuticalsTerminatedPrimary completion: 2023-01-19 · Actual

Trial details

Jazz PharmaceuticalsTerminatedPrimary completion: 2022-12-31 · Actual

Trial details

Jazz PharmaceuticalsTerminatedPrimary completion: 2023-04-17 · Actual

Trial details

Jazz PharmaceuticalsRecruitingPrimary completion: 2028-06 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.